F S&P 500
5,839.75 -1.50 (-0.03%) F Dow Jones
42,817.00 +4.00 (+0.01%) F Nasdaq
20,463.75 +0.25 (+0.00%) E-mini Russell 2000 Index Futur
2,215.40 -2.90 (-0.13%) Petróleo
73.91 +0.67 (+0.91%) Oro
2,632.20 +6.20 (+0.24%)
bluebird bio, Inc. (BLUE)
Fuera de horario:
bluebird bio, Inc.
455 Grand Union Boulevard
Somerville, MA 02145
United States
339 499 9300
https://www.bluebirdbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 375
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Andrew Obenshain | President, CEO & Director | 1.04M | N/D | 1974 |
| Mr. Thomas J. Klima | Chief Commercial Officer & COO | 676.68k | N/D | 1972 |
| Mr. Richard A. Colvin M.D., Ph.D. | Chief Medical Officer | 691.4k | N/D | 1966 |
| Mr. Oliver James Sterling III | CFO & Principal Accounting Officer | N/D | N/D | N/D |
| Mr. Joseph D. Vittiglio Esq., J.D. | Chief Legal & Business Officer and Secretary | N/D | N/D | 1972 |
| Jess Rowlands | Head of Corporate Communications | N/D | N/D | N/D |
| Ms. Andrea Walton | Chief People Officer | N/D | N/D | N/D |
| Mr. Kasra Kasraian | Senior Vice President of Technical Development & Operations | N/D | N/D | N/D |
| Mr. Scott Shoemaker | Senior Vice President of Quality | N/D | N/D | N/D |
| Ms. Sarah Alspach | Senior Vice President of External Affairs | N/D | N/D | N/D |
Descripción
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de bluebird bio, Inc. a partir del 1 de octubre de 2024 es 5. Las puntuaciones principales son Auditoría: 9; Junta: 3; Derechos del accionista: 5; Compensación: 5.
